Nexalin Technology has secured a significant 10-year exclusive distribution agreement with Inovanexa Medical Technologies for its Nexalin Sync device across seven Latin American markets. This deal includes an initial 100-device commercialization program and minimum revenue thresholds, positioning the company for substantial international expansion and recurring royalty revenue.
Nexalin Technology (NXL) has signed a definitive 10-year exclusive distribution agreement with Inovanexa Medical Technologies for its ANVISA-approved Nexalin Sync device across seven Latin American countries, including Brazil. This agreement is a major step for NXL, converting two years of groundwork into a concrete commercial launch platform for a region with over 300 million people and a high prevalence of mental health disorders. The deal includes an initial 100-device commercialization program, minimum revenue thresholds, and a distributor-funded manufacturing framework designed to generate recurring royalty revenue. This represents a significant long-term growth opportunity for NXL, potentially boosting its revenue streams and market penetration in a key emerging market.